KLRK1 and neoplasm: NK cells, engineered using a genomically-stable and clinically-safe non-viral vector system to target NKG2D ligands via DAP10 and CD3ζ co-signaling domains based on the piggyBac transposon system, could mediate a powerful anti-tumor response in conjunction with purinergic blockade (Scheme 1b).